Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
ABBV-400 by AbbVie for Melanoma: Likelihood of Approval
ABBV-400 is under clinical development by AbbVie and currently in Phase I for Melanoma. According to GlobalData, Phase I drugs...
ABBV-400 by AbbVie for Uterine Cancer: Likelihood of Approval
ABBV-400 is under clinical development by AbbVie and currently in Phase I for Uterine Cancer. According to GlobalData, Phase I...
ABBV-400 by AbbVie for Non-Small Cell Lung Cancer: Likelihood of Approval
ABBV-400 is under clinical development by AbbVie and currently in Phase I for Non-Small Cell Lung Cancer. According to GlobalData,...
ABBV-400 by AbbVie for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval
ABBV-400 is under clinical development by AbbVie and currently in Phase I for Head And Neck Squamous Cell Carcinoma (HNSC)....
ABBV-400 by AbbVie for Squamous Non-Small Cell Lung Cancer: Likelihood of Approval
ABBV-400 is under clinical development by AbbVie and currently in Phase I for Squamous Non-Small Cell Lung Cancer. According to...
Risk adjusted net present value: What is the current valuation of AbbVie's ABBV-400?
ABBV-400 is a monoclonal antibody conjugated commercialized by AbbVie, with a leading Phase II program in Metastatic Colorectal Cancer. According...
ABBV-400 by AbbVie for Colorectal Cancer: Likelihood of Approval
ABBV-400 is under clinical development by AbbVie and currently in Phase I for Colorectal Cancer. According to GlobalData, Phase I...
ABBV-400 by AbbVie for Gastric Cancer: Likelihood of Approval
ABBV-400 is under clinical development by AbbVie and currently in Phase I for Gastric Cancer. According to GlobalData, Phase I...
ABBV-400 by AbbVie for Solid Tumor: Likelihood of Approval
ABBV-400 is under clinical development by AbbVie and currently in Phase I for Solid Tumor. According to GlobalData, Phase I...
ABBV-400 by AbbVie for Renal Cell Carcinoma: Likelihood of Approval
ABBV-400 is under clinical development by AbbVie and currently in Phase I for Renal Cell Carcinoma. According to GlobalData, Phase...
ABBV-400 by AbbVie for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval
ABBV-400 is under clinical development by AbbVie and currently in Phase I for Adenocarcinoma Of The Gastroesophageal Junction. According to...
ABBV-400 by AbbVie for Metastatic Hepatocellular Carcinoma (HCC): Likelihood of Approval
ABBV-400 is under clinical development by AbbVie and currently in Phase I for Metastatic Hepatocellular Carcinoma (HCC). According to GlobalData,...
ABBV-400 by AbbVie for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
ABBV-400 is under clinical development by AbbVie and currently in Phase I for Pancreatic Ductal Adenocarcinoma. According to GlobalData, Phase...
ABBV-400 by AbbVie for Metastatic Colorectal Cancer: Likelihood of Approval
ABBV-400 is under clinical development by AbbVie and currently in Phase II for Metastatic Colorectal Cancer. According to GlobalData, Phase...
ABBV-400 by AbbVie for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval
ABBV-400 is under clinical development by AbbVie and currently in Phase I for Human Epidermal Growth Factor Receptor 2 Negative...
ABBV-400 by AbbVie for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
ABBV-400 is under clinical development by AbbVie and currently in Phase I for Triple-Negative Breast Cancer (TNBC). According to GlobalData,...
ABBV-400 by AbbVie for Esophageal Squamous Cell Carcinoma (ESCC): Likelihood of Approval
ABBV-400 is under clinical development by AbbVie and currently in Phase I for Esophageal Squamous Cell Carcinoma (ESCC). According to...
ABBV-400 by AbbVie for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval
ABBV-400 is under clinical development by AbbVie and currently in Phase I for Bile Duct Cancer (Cholangiocarcinoma). According to GlobalData,...